Experimental Hematology & Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2020-08-04 chenyanhui377

审稿速度:1.0 | 版面费用:2490.0
偏重的研究方向：肿瘤免疫治疗;生物标志物
经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。

144 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-08-28 ms1000000858912769

1 Reviewer(s) accepted 24 Aug 22
Awaiting their report
这是送外审了吗

60 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-09-21 ms1000000858912769

两个审稿人意见回来一周了还在等编辑decision……

64 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-11-19 14754588m76暂无昵称

审稿速度:2.0
偏重的研究方向：肿瘤转移
经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-12-18 14754588m76暂无昵称来自重庆

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了.

47 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-10-31 14828bdem32暂无昵称

请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-03-10 ms9000001164779330 来自北卡罗来纳

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：9-13 投稿
9-21 editor appointed
10-1 邀请审稿人
2-2 全部审稿人意见收回，等待编辑决定
2-6 修回-小修
2-12 1返修回去
2-13 编辑手里
2-21 再邀审稿人
3-6 编辑决定
3-7 接收

45 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-05-30 ms2000001557611905

我的reviewers invited 状态两个月，感觉找不到审稿人。。。

45 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-28 小动量

推荐同行评议时需要注意哪些情况？

42 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=806121, encodeId=94d0806121aa, content=审稿速度:1.0 | 版面费用:2490.0 偏重的研究方向：肿瘤免疫治疗;生物标志物 经验分享：审稿速度较快，一审三周后返回审稿意见，修改后一周接受。编辑比较友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11341515923, createdName=chenyanhui377, createdTime=Tue Aug 04 14:46:16 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241457, encodeId=eaf1124145ef1, content=1 Reviewer(s) accepted 24 Aug 22 Awaiting their report 这是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Sun Aug 28 09:18:41 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089465, encodeId=d23720894653d, content=两个审稿人意见回来一周了还在等编辑decision……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Sep 21 08:13:50 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101571, encodeId=d37d21015e13f, content=审稿速度:2.0 偏重的研究方向：肿瘤转移 经验分享：显示1 Reviewer report received已经马上1个月了,大家有类似经历吗,应该发邮件催吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sat Nov 19 23:27:38 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106596, encodeId=92da2106596d3, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：审稿真TM是个变态慢,着急毕业的同学慎重投,宣传说审稿很快,其实是个水货,审稿快3个月了还没有动静,真是服了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04a85208307, createdName=14754588m76暂无昵称, createdTime=Sun Dec 18 17:24:39 CST 2022, time=2022-12-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097551, encodeId=1ff4209e55170, content=请问各位前辈，我前几天投了一篇文章，怎么找到看审稿进度的界面呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Mon Oct 31 09:29:16 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118636, encodeId=3f32211863654, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9-13 投稿 9-21 editor appointed 10-1 邀请审稿人 2-2 全部审稿人意见收回，等待编辑决定 2-6 修回-小修 2-12 1返修回去 2-13 编辑手里 2-21 再邀审稿人 3-6 编辑决定 3-7 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9376527426, createdName=ms9000001164779330, createdTime=Fri Mar 10 11:01:29 CST 2023, time=2023-03-10, status=1, ipAttribution=北卡罗来纳), GetPortalCommentsPageByObjectIdResponse(id=1223281, encodeId=d3e31223281c0, content=我的reviewers invited 状态两个月，感觉找不到审稿人。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2e25481580, createdName=ms2000001557611905, createdTime=Mon May 30 05:59:18 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113759, encodeId=5dd61113e5956, content=推荐同行评议时需要注意哪些情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113760, encodeId=9c9f1113e6059, content=什么是correspondingauthor/通讯作者？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 MS68862005

什么是correspondingauthor/通讯作者？

45 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务